Lasa Supergenerics Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (API) bulk drugs products. The Company is engaged in the business of manufacturing, trading, producing, processing, preparing, and treating chemicals, API, pharmaceuticals, drugs, and others. It specializes in catalyst chemistry and manufactures anthelmintic/ veterinary API products with production capabilities and product categories in India. The Company's products include API products, other API products, animal feed ingredients and reagents for therapeutic use. Its API products include Fenbendazole, Toldimphos sodium, Cyromazine, Albendazole, Riclabendazole, Rafoxanide, Ornidazole, 2,6-Diiodo-4-Nitrophenol, Ricobendazole, Oxfendazole, Closantel Base, Closantel sodium, Nitroxynil, Halquinol, and Oxyclozanide. The Company's manufacturing facility is located in Chiplun, Maharashtra.
Lasa Supergenics Financial Highlights
- Revenue: Lasa Supergenics reported revenue of ₹25.34 crore in FY26 vs ₹147.46 crore in FY25. It showed a decrease of 82.82% on a yearly basis.
- Operating Profit: Lasa Supergenics reported an operating loss of ₹34.61 crore in FY26 vs ₹19.38 crore in FY25. It showed a decrease of 78.59% on a year-on-year basis.
- Net Profit: Lasa Supergenics reported a net loss of ₹34.09 crore in FY26 vs ₹14.76 crore in FY25. It showed a decrease of 130.96% on a yearly basis.
Lasa Supergenics Quarterly Result Highlights
- Lasa Supergenics reported revenue of ₹0.09 crore in Mar 2026, compared with ₹2.22 crore in Dec 2025, representing a decrease of 104.05% on a quarter-on-quarter (QoQ) basis.
- Lasa Supergenics reported an operating loss of ₹3.98 crore in Mar 2026, compared with ₹2.41 crore in Dec 2025, representing a decrease of 65.15% on a quarter-on-quarter (QoQ) basis.
- Lasa Supergenics reported a loss of ₹4.16 crore in Mar 2026, compared with ₹2.55 crore in Dec 2025, reflecting a decrease of 63.14% on a QoQ basis.
- The earnings per share (EPS) of Lasa Supergenics stood at ₹2.95 during Mar 2026.